1-5 of 5
Luke Dreisbach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Clemens Wendtner, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, M.D., Lutz Uharek, Steven Coutre, Olga Frankfurt, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Richard R. Furman, MD, Eva Kimby, John G. Gribben, MD, DSc, Marco Gobbi, MD, Luke Dreisbach, MD, David Duane Hurd, MD, Mikkael A. Sekeres, MD, MS, Alessandra Ferrajoli, MD, Sheetal Shah, Jennie Zhang, Laure Moutouh de Parseval, MD, Asher A. Chanan-Khan
Journal: Blood
Blood (2010) 116 (21): 1376.
https://doi.org/10.1182/blood.V116.21.1376.1376
Published: 2010
Journal Articles

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M Lyons, Richard A. Larson, MD, Michael A. Kosmo, MD, Sunil Gandhi, Delong Liu, MD, PhD, Marc Chernoff, Luke Dreisbach, MD, Carmen Matei, Kuolong Hu, PhD, Janet L. Franklin, MD, MPH, Dietmar Berger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1770.
https://doi.org/10.1182/blood.V114.22.1770.1770
Published: 2009
Journal Articles

TROPICS 2: A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters.

Cameron Tebbi, MD, John Costanzi, MD, Robert J Shulman, MD, Luke Dreisbach, MD, Brian R Jacobs, MD, Martha Blaney, PharmD, Mark Ashby, PhD, Barbara S Gillespie, MD, Susan M Begelman, MD
Journal: Blood
Blood (2009) 114 (22): 1074.
https://doi.org/10.1182/blood.V114.22.1074.1074
Published: 2009
Journal Articles

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Clinical Trials & Observations
Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List
Journal: Blood
Blood (2008) 111 (1): 86–93.
https://doi.org/10.1182/blood-2007-01-068833
Published: 2008
Includes: Supplemental data
Journal Articles

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Azra Raza, MD, James E. Reeves, MD, Eric J. Feldman, MD, H. Joachim Deeg, MD, Luke Dreisbach, MD, Charles A. Schiffer, MD, Jamile M. Shammo, MD, Virginia M. Klimek, MD, Peter L. Greenberg, MD, John M. Bennett, MD, Gordon W. DeWald, PhD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RN,C, Robert D. Knight, MD, Alan F. List, MD
Journal: Blood
Blood (2006) 108 (11): 250.
https://doi.org/10.1182/blood.V108.11.250.250
Published: 2006